

# FY4/25 Supplementary Materials

# AIN HOLDINGS INC.

June 5, 2025

# 1. Consolidated Results

### ■ Year-on-Year

(¥ million)	FY4/24 results	FY4/25 results	YoY change	YoY change(%)
Net sales	399,824	456,804	+56,980	+14.3
Gross profit	59,522	74,436	+14,914	+25.1
% of net sales	14.9	16.3		
SG&A expenses	39,090	57,565	+18,475	+47.3
% of net sales	9.8	12.6		
Operating profit	20,432	16,871	(3,561)	(17.4)
% of net sales	5.1	3.7		
Ordinary profit	21,377	18,080	(3,297)	(15.4)
% of net sales	5.3	4.0		
Profit attributable to owners of parent	11,401	9,261	(2,140)	(18.8)
% of net sales	2.9	2.0		
Profit per share(¥)	324.64	264.32	(60.32)	(18.6)

Figures in the table are rounded down

# **■Vs Plan**

(¥ million)	FY4/25 plan	FY4/25 results	Vs plan change	Vs plan change(%)
Net sales	453,500	456,804	+3,304	+0.7
Gross profit	76,200	74,436	(1,764)	(2.3)
% of net sales	16.8	16.3		
SG&A expenses	56,840	57,565	+725	+1.3
% of net sales	12.5	12.6		
Operating profit	19,360	16,871	(2,489)	(12.9)
% of net sales	4.3	3.7		
Ordinary profit	20,000	18,080	(1,920)	(9.6)
% of net sales	4.4	4.0		
Profit attributable to owners of parent	10,000	9,261	(739)	(7.4)
% of net sales	2.2	2.0		
Profit per share(¥)	285.68	264.32	(21.36)	(7.5)

- Figures in the table are rounded down
- Plan is the revised plan disclosed in Sept. 2024

# 2. Segment Information (Dispensing Pharmacy Business)

### ■ Year-on-Year

(¥ million)	FY4/24 results	FY4/25 results	YoY change	YoY change(%)
Net sales	357,571	384,783	+27,212	+7.6
Gross profit	43,575	40,485	(3,090)	(7.1)
% of net sales	12.2	10.5		
SG&A expenses	16,949	17,708	+759	+4.5
% of net sales	4.7	4.6		
Operating profit	26,625	22,776	(3,849)	(14.5)
% of net sales	7.4	5.9		
Segment profit	27,587	24,286	(3,301)	(12.0)
% of net sales	7.7	6.3		

Figures in the table are rounded down

#### ■ Vs Plan

(¥ million)	FY4/25 plan	FY4/25 results	Vs plan change	Vs plan change(%)
Net sales	380,000	384,783	+4,783	+1.3
Gross profit	42,700	40,485	(2,215)	(5.2)
% of net sales	11.2	10.5		
SG&A expenses	18,100	17,708	(392)	(2.2)
% of net sales	4.8	4.6		
Operating profit	24,600	22,776	(1,824)	(7.4)
% of net sales	6.5	5.9		
Segment profit	25,300	24,286	(1,014)	(4.0)
% of net sales	6.7	6.3		

- Figures in the table are rounded down
- Plan is the revised plan disclosed in Sept. 2024
- Segment profit is adjusted with ordinary profit shown on the consolidated statement of income

<sup>&</sup>gt; Segment profit is adjusted with ordinary profit shown on the consolidated statement of income

# 3. Segment Information (Retail Business)

#### ■ Year-on-Year

(¥ million)	FY4/24 results	FY4/25 results	YoY change	YoY change(%)
Net sales	31,111	61,041	+29,930	+96.2
Gross profit	11,967	30,030	+18,063	+150.9
% of net sales	38.5	49.2		
SG&A expenses	8,913	25,248	+16,335	+183.3
% of net sales	28.6	41.4		
Operating profit	3,054	4,782	+1,728	+56.6
% of net sales	9.8	7.8		
Segment profit	3,096	4,804	+1,708	+55.2
% of net sales	10.0	7.9		

Figures in the table are rounded down

### ■ Vs Plan

(¥ million)	FY4/25 plan	FY4/25 results	Vs plan change	Vs plan change(%)
Net sales	61,290	61,041	(249)	(0.4)
Gross profit	29,120	30,030	+910	+3.1
% of net sales	47.5	49.2		
SG&A expenses	24,395	25,248	+853	+3.5
% of net sales	39.8	41.4		
Operating profit	4,725	4,782	+57	+1.2
% of net sales	7.7	7.8		
Segment profit	4,720	4,804	+84	+1.8
% of net sales	7.7	7.9		

- Figures in the table are rounded down
- Plan is the revised plan disclosed in Sept. 2024
- Segment profit is adjusted with ordinary profit shown on the consolidated statement of income

Segment profit is adjusted with ordinary profit shown on the consolidated statement of income

# 4. Sales Verification

Total (157)

■ Dispensing Pharmacy Business (YoY)

(%)	Net sales	Prescription volume	Average prescription price	(%)	Net sales	Prescription volume	Average prescription price		
Same store (1,153)	+3.8	+0.7	+3.1	Same store (1,153)	+1.6	(0.5)	+2.1		
Store openings in the previous year (39)	+174.5	+152.3	+8.8	Store openings in the previous year (39)	+9.6	+0.7	+8.7		
Total (1,290)	+7.7	+4.0	+3.5	Total (1,290)	+1.3	(1.0)	+2.3		
	■ Retail Business (YoY)  AINZ & TULPE + Francfranc				<ul><li>Retail Business (Vs Plan)</li><li>AINZ &amp; TULPE + Francfranc</li></ul>				
(%)	Net sales	Number of customers	Average spending per customer	(%)	Net sales	Number of customers	Average spending per customer		
Same store (73)	+9.7	+4.7	+4.8	Same store (73)	(0.1)	+1.1	(1.2)		
Store openings in the previous year (6)	+148.4	+141.4	+2.9	Store openings in the previous year (6)	+7.7	+9.9	(2.0)		
Total (260)	+93.5	+61.7	+19.7	Total (260)	(1.8)	(0.7)	(1.0)		
AINZ & TULPE	<b>=</b>			AINZ & TULP	E				
(%)	Net sales	Number of customers	Average spending per customer	(%)	Net sales	Number of customers	Average spending per customer		
Same store (73)	+9.7	+4.7	+4.8	Same store (73)	(0.1)	+1.1	(1.2)		
Store openings in the previous year (6)	+148.4	+141.4	+2.9	Store openings in the previous year (6)	+7.7	+9.9	(2.0)		
Total (95)	+15.8	+11.8	+3.6	Total (95)	+0.1	+1.0	(0.9)		
Francfranc				Francfranc					
(%)	Net sales	Number of customers	Average spending per customer	(%)	Net sales	Number of customers	Average spending per customer		

■ Dispensing Pharmacy Business (Vs Plan)

(4.4)

(4.4)

(1.2)

Total (157)

Plan and results of Francfranc are only domestic stores and it's own e-commerce site

# 5. Consolidated Balance Sheet

### ■ Assets

(¥ million)	End-FY4/23	End-FY4/24	End-FY4/25	Change
Cash and deposits	46,796	48,611	26,881	(21,730)
Accounts receivable - trade	13,249	15,852	22,295	+6,443
Inventories	21,586	24,645	36,071	+11,426
Total current assets	98,305	110,743	112,808	+2,065
Buildings and structures, net	21,407	27,122	31,648	+4,526
Land	10,602	10,207	10,218	+11
Total property, plant and equipment	39,459	43,450	49,712	+6,262
Goodwill	46,443	44,066	84,772	+40,706
Total intangible assets	52,343	51,242	97,621	+46,379
Investments securities	2,720	3,345	3,233	(112)
Deferred tax assets	5,990	6,403	7,679	+1,276
Leasehold and guarantee deposits	24,507	25,186	31,091	+5,905
Total investments and other assets	41,641	43,973	51,778	+7,805
Total non-current assets	133,444	138,666	199,112	+60,446
Total assets	231,750	249,409	311,921	+62,512

Figures in the table are rounded down

Change: End-FY4/25 compared with end-FY4/24

### ■ Liabilities and Net Assets

(¥ million)	End-FY4/23	End-FY4/24	End-FY4/25	Change
Accounts payable – trade	58,698	65,506	80,895	+15,389
Short-term borrowings	3,670	3,467	12,151	+8,684
Total current liabilities	92,986	103,232	132,045	+28,813
Long-term borrowings	5,021	3,227	26,469	+23,242
Total non-current liabilities	12,218	10,765	37,243	+26,478
Total liabilities	105,204	113,998	169,288	+55,290
Share capital	21,894	21,894	21,894	-
Capital surplus	20,504	20,131	20,128	(3)
Retained earnings	85,963	95,257	101,692	+6,435
Total shareholders' equity	126,362	134,847	141,717	+6,870
Total net assets	126,546	135,411	142,632	+7,221
Total liabilities and net assets	231,750	249,409	311,921	+62,512

Figures in the table are rounded down

Capital expenditures (Property, plant and equipment and intangible assets + Leasehold and guarantee deposits) totaled ¥17,234 million

Change: End-FY4/25 compared with end-FY4/24

# 6. FY4/26 Plan (Consolidated)

(¥ million)	FY4/24 results	FY4/25 results	FY4/26 plan	YoY change	YoY change (%)
Net sales	399,824	456,804	522,000	+65,196	+14.3
Gross profit	59,522	74,436	93,323	+ 18,887	+25.4
% of net sales	14.9	16.3	17.9		
SG&A expenses	39,090	57,565	71,463	+13,898	+24.1
% of net sales	9.8	12.6	13.7		
Operating profit	20,432	16,871	21,860	+4,989	+29.6
% of net sales	5.1	3.7	4.2		
Ordinary profit	21,377	18,080	22,100	+4,020	+22.2
% of net sales	5.3	4.0	4.2		
Profit attributable to owners of parent	11,401	9,261	11,450	+2,189	+23.6
% of net sales	2.9	2.0	2.2		
Profit per share(¥)	324.64	262.32	326.46	+62.14	+23.5
Annual dividend(¥)	80.00	80.00	80.00	-	0.0

Figures in the table are rounded down

The impact of the acquisition of Sakura Pharmacy Group as a subsidiary, announced on May 29, 2025, is not incorporated into the plan for FY4/26

# 7. FY4/26 Plan (Segment)

# ■ Dispensing Pharmacy Business

(¥ million)	FY4/24 results	FY4/25 results	FY4/26 plan	YoY change	YoY change (%)
Net sales	357,571	384,783	427,500	+42,717	+11.1
Gross profit	43,575	40,485	46,270	+5,785	+14.3
% of net sales	12.2	10.5	10.8		
SG&A expenses	16,949	17,708	20,200	+2,492	+14.1
% of net sales	4.7	4.6	4.7		
Operating profit	26,625	22,776	26,070	+3,294	+14.5
% of net sales	7.4	5.9	6.1		
Segment profit	27,587	24,286	26,810	+2,524	+10.4
% of net sales	7.7	6.3	6.3		

- Figures in the table are rounded down
- Segment profit is adjusted with ordinary profit shown on the consolidated statement of income
- The impact of the acquisition of Sakura Pharmacy Group as a subsidiary, announced on May 29, 2025, is not incorporated into the plan for FY4/26

#### ■ Retail Business

(¥ million)	FY4/24 results	FY4/25 results	FY4/26 plan	YoY change	YoY change (%)
Net sales	31,111	61,041	83,100	+22,059	+36.1
Gross profit	11,967	30,030	43,090	+13,060	+43.5
% of net sales	38.5	49.2	51.9		
SG&A expenses	8,913	25,248	35,590	+10,342	+41.0
% of net sales	28.6	41.4	42.8		
Operating profit	3,054	4,782	7,500	+2,718	+56.8
% of net sales	9.8	7.8	9.0		
Segment profit	3,096	4,804	7,500	+2,696	+56.1
% of net sales	10.0	7.9	9.0		

- Figures in the table are rounded down
- Segment profit is adjusted with ordinary profit shown on the consolidated statement of income

## 8. Transition of Store Openings

# ■ Number of Store Openings in Dispensing Pharmacy Business

	FY4/17	FY4/18	FY4/19	FY4/20	FY4/21	FY4/22	FY4/23	FY4/24	FY4/25
Organic	27	25	23	14	15	25	27	19	30
M&A	182	11	134	6	14	24	114	21	68
Total	1,066	1,029	1,132	1,088	1,065	1,099	1,209	1,231	1,290

## ■ Number of Store Openings in Retail Business

	FY4/17	FY4/18	FY4/19	FY4/20	FY4/21	FY4/22	FY4/23	FY4/24	FY4/25
AINZ & TULPE	9	4	7	15	11	12	8	6	16
Francfranc	-	-	-	-	-	-	-	-	167
Total	52	48	54	63	69	78	78	81	260

### Inquiries related to this presentation should be addressed to

AIN HOLDINGS INC.
Corporate Planning Division
TEL: +81-3-5333-1812
https://www.ainj.co.jp/corporate/

This document may not be reproduced or distributed to any third party without prior approval of AIN HOLDINGS INC. This document has been prepared for information purpose only and does not form part of a solicitation to sell or purchase any securities. Information contained herein may be changed or revised without prior notice. This document may contain forecasting statements as to future results of operations. No forecast statement can be quaranteed and actual results of operations may differ from those projected.

